Qiagen (NYSE:QGEN) Holdings Raised by Natixis Advisors L.P.

Natixis Advisors L.P. increased its position in shares of Qiagen (NYSE:QGEN) by 101.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 598,279 shares of the company’s stock after purchasing an additional 301,003 shares during the quarter. Natixis Advisors L.P. owned 0.27% of Qiagen worth $25,983,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in QGEN. Briaud Financial Planning Inc acquired a new position in Qiagen in the third quarter valued at approximately $31,000. Toronto Dominion Bank acquired a new position in Qiagen during the 3rd quarter valued at approximately $41,000. Lindbrook Capital LLC grew its stake in Qiagen by 21.6% during the 4th quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after buying an additional 237 shares during the last quarter. Blue Trust Inc. grew its stake in Qiagen by 253.9% during the 4th quarter. Blue Trust Inc. now owns 3,974 shares of the company’s stock worth $161,000 after buying an additional 2,851 shares during the last quarter. Finally, Signaturefd LLC increased its position in Qiagen by 9.0% in the third quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock worth $190,000 after buying an additional 385 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on QGEN. Morgan Stanley raised shares of Qiagen from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $49.48 to $51.00 in a report on Friday, February 16th. Stifel Nicolaus decreased their target price on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday. Citigroup cut their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, February 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.95.

Qiagen Stock Performance

QGEN opened at $42.98 on Friday. The business has a 50 day moving average price of $42.53 and a two-hundred day moving average price of $42.75. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.62. The company has a market capitalization of $9.81 billion, a price-to-earnings ratio of 28.82, a price-to-earnings-growth ratio of 3.64 and a beta of 0.42. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.70.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company’s revenue was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.53 earnings per share. Research analysts predict that Qiagen will post 2.09 EPS for the current fiscal year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.